Document is current
Any future updates will be listed below
-
Authors
Eadie, L N
Dang, P
Saunders, V A
Yeung, D T
Osborn, M P
Grigg, A P
Hughes, T P
White, D L
- License Information
-
More Information
Article History
Received: 29 November 2015
Revised: 7 June 2016
Accepted: 10 June 2016
First Online: 24 June 2016
Competing interests
: LNE, PD, VAS, MPO and APG have no conflict of interest to declare. DTY, TPH and DLW receive honoraria and research funds from Novartis Pharmaceuticals, and are members of Advisory Boards for Novartis. DTY and TPH are chairs of the CML/MPN disease group for the Australasian Leukaemia and Lymphoma Group (ALLG). Neither Novartis nor ALLG had roles in the design of the study, collection and analysis of the data or the decision to publish.
